# Stephen J. Hoffman

> Stephen J. Hoffman is a Series B investor at Apic Bio backing Medical and Biotechnology. See 16 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Apic Bio](https://shizune.co/investors/profile/apic-bio)
- Total investments: 16
- Last investment: Mar 2015
- Lead investor: 19%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/sjhoffmanphdmd

Stephen J. Hoffman is a Series B investor at Apic Bio focused on Medical and Biotechnology. Stephen J. Hoffman - Chairman @ Apic Bio

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 4 | 25% |
| Biotechnology | 4 | 25% |
| Health Care | 1 | 6% |
| Life Science | 1 | 6% |
| Therapeutics | 1 | 6% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 25% |
| Series C | 3 | 19% |
| Series A | 1 | 6% |
| Series D | 1 | 6% |
| Funding Round | 1 | 6% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Collegium Pharmaceutical | Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focusedon building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform. | $50M | Private Equity | Mar 10, 2015 |  |
| Proteon Therapeutics | Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $45M | Series D | May 16, 2014 |  |
| Genocea Biosciences | Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalizedcancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. |  | Series C | Oct 10, 2012 |  |
| Collegium Pharmaceutical | Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focusedon building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform. | $22.5M |  | Feb 15, 2012 |  |
| Collegium Pharmaceutical | Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focusedon building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform. |  | Series B | Feb 15, 2012 |  |
| Proteon Therapeutics | Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $15.2M | Series C | Aug 12, 2011 |  |
| Genocea Biosciences | Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalizedcancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. | $35M | Series B | Jan 03, 2011 |  |
| Genocea Biosciences | Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalizedcancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. | $18.6M | Series B | Dec 01, 2009 |  |
| Proteon Therapeutics | Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $50M | Series B | May 28, 2009 |  |
| Concert Pharmaceuticals | Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline ofnew chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense. | $37M | Series C | Apr 30, 2008 |  |

10 of 16 investments shown.

## Co-investors
- [Greylock](https://shizune.co/investors/profile/greylock) — VC Fund, 6 deals together
- [QVT Financial](https://shizune.co/investors/profile/qvt-financial) — VC Fund, 6 deals together
- [Three Arch Partners](https://shizune.co/investors/profile/three-arch-partners) — VC Fund, 6 deals together
- [TVM Capital](https://shizune.co/investors/profile/tvm-capital) — VC Fund, 6 deals together
- [Brookside Capital](https://shizune.co/investors/profile/brookside-capital) — VC Fund, 4 deals together
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 4 deals together

## About Apic Bio

VC Fund · Cambridge, United States

Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases. The company is advancing several novel gene therapies to treat Alpha-1 Antitrypsin Deficiency (Alpha-1), genetic Amyotrophic Lateral Sclerosis (ALS), and other CNS diseases.

4 contacts available at Apic Bio.

| Name | Title | Profile |
| --- | --- | --- |
| Christian Mueller | Co Founder | https://shizune.co/investors/profile/christian-mueller-94bf |
| Daniel Geffken | Interim Chief Financial Officer | https://shizune.co/investors/profile/daniel-geffken |
| John Reilly | Co-Founder/President & CEO | https://shizune.co/investors/profile/john-reilly-4 |
| Stephen J. Hoffman | Chairman | https://shizune.co/investors/profile/stephen-j-hoffman |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Stephen J. Hoffman invest in?

Stephen J. Hoffman invests primarily in Medical, Biotechnology and Health Care startups, most often at Series B and Series C stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Stephen J. Hoffman last invest?

The most recent investment recorded for Stephen J. Hoffman closed in Mar 2015. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co